Dr. Mary Walton
Alzheimer's dementia (AD) affects millions of people worldwide each year. The incidence of AD contributes to rising global healthcare costs. Guidance is limited for routine screening despite the prevalence of AD. Characterizing AD from the various types of dementia is significant in identifying disease-specific symptoms. The current approach to evaluate cognitive decline consists of cognitive and neuropsychic testing, neuroimaging, and baseline laboratory screening for infectious and metabolic abnormalities. These assays are cost-effective and readily available but rarely provide a definitive diagnosis. Novel serum and neuroimaging biomarkers may provide immediate diagnosis at the onset of mild cognitive impairment or, in some cases, before symptom onset. Early detection of these biomarkers is vital to understanding the disease process, progression, and management. Expedient recognition of AD is crucial to support appropriate disease-modifying treatment. This article aims to provide a review of emerging modalities to promote early AD detection.
Driver-Phillips L. Early Detection of Alzheimer's Dementia. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.